The BCS, BDDCS, and Regulatory Guidances
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The Biopharmaceutics Classification System (BCS), based on aqueous solubility and intestinal permeability, has enjoyed wide use since 1995 as a mechanism for waiving in vivo bioavailability and bioequivalence studies.”
From BCS Biowaivers: Similarities and Differences Among EMA, FDA, and WHO Requirements (2016) · cites this paper as [5]
In the citing paper
“Another premise underlying the development of the BCS is the recognition that the two key factors governing drug absorption are aqueous solubility and intestinal permeability (5).”
From BCS Biowaivers: Similarities and Differences Among EMA, FDA, and WHO Requirements (2016) · cites this paper as [5]
In the citing paper
“Thus, the BCS is now widely established in the academic, industrial, and regulatory world for waiving the regulatory requirements of conducting comparative bioavailability studies to demonstrate in vivo BA/BE of immediate-release (IR) solid oral dosage forms containing BCS Class I and Class III drugs (5,6).”
From BCS Biowaivers: Similarities and Differences Among EMA, FDA, and WHO Requirements (2016) · cites this paper as [5]
Citations
Cites
Amidon, G. L., Lennernäs, H., Shah, V. P., & Crison, J. R. (1995) · Pharmaceutical Research · doi:10.1023/a:1016212804288 · Cited by 5,430 · cited 4×
“The BCS (Biopharmaceutics Classification System), based on aqueous solubility and intestinal permeability, has been widely used since 1995 to predict drug absorption during the course of pharmaceutical development (1).”
BackgroundMethodInfluentialSelf-citationArtursson, P., Palm, K., & Luthman, K. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00128-9 · Cited by 1,543
Wu, C.-Y., & Benet, L. Z. (2005) · Pharmaceutical Research · doi:10.1007/s11095-004-9004-4 · Cited by 1,401 · cited 3×
“In view of the apparent correlation between drug metabolism and intestinal permeability rate, it was further suggested that extensive drug metabolism may provide an alternate (or additional) tool for characterizing high intestinal permeability under BCS (4,5).”
BackgroundMethodSelf-citation(2001) · Drugs and the Pharmaceutical Sciences · doi:10.1201/9780824741969.axh · Cited by 818
Takagi, T., Ramachandran, C., Bermejo, M., Yamashita, S., Yu, L. X., & Amidon, G. L. (2006) · Molecular Pharmaceutics · doi:10.1021/mp0600182 · Cited by 606
Self-citationBiopharmaceutics Classification System: The Scientific Basis for Biowaiver Extensions
Yu, L. X., Amidon, G. L., Polli, J. E., Zhao, H., Mehta, M. U., Conner, D. P., Shah, V. P., Lesko, L. J., Chen, M.-L., Lee, V. H. L., et al. (2002) · Pharmaceutical Research · doi:10.1023/a:1016473601633 · Cited by 571 · cited 2×
“other drug products in immediate release solid oral dosage forms (18).”
BackgroundSelf-citationIntestinal permeability and its relevance for absorption and elimination
Lennernäs, H. (2007) · Xenobiotica · doi:10.1080/00498250701704819 · Cited by 304 · cited 3×
“permeability by the single-pass perfusion technique at steady-state, and the measured permeability was found to be correlated with the fraction of oral dose absorbed for 34 compounds with different structural diversity (9,10).”
BackgroundYazdanian, M., Briggs, K., Jankovsky, C., & Hawi, A. (2004) · Pharmaceutical Research · doi:10.1023/b:pham.0000016242.48642.71 · Cited by 290
Human Jejunal Effective Permeability and Its Correlation with Preclinical Drug Absorption Models
LennernÄs, H. (1997) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.1997.tb06084.x · Cited by 223 · cited 2×
“of in vivo studies on 34 drugs and endogenous substances, wherein a good correlation was established between jejunal permeability obtained from human intestinal perfusion studies and the fraction of oral dose absorbed using pharmacokinetic studies in humans (10).”
BackgroundLennernäs, H., & Abrahamsson, B. (2005) · Journal of Pharmacy and Pharmacology · doi:10.1211/0022357055263 · Cited by 215 · cited 2×
“adoption of these new criteria and possible extension of biowaivers (16,18).”
Background
Cited by
Strategies to Address Low Drug Solubility in Discovery and Development
Williams, H. D., Trevaskis, N. L., Charman, S. A., Shanker, R. M., Charman, W. N., Pouton, C. W., & Porter, C. J. H. (2013) · Pharmacological Reviews · doi:10.1124/pr.112.005660 · Cited by 1,570
“4), originally developed by Amidon et al. (1995), with subsequent variations by others (Wu and Benet, 2005; Butler and Dressman, 2010; Chen et al., 2011).”
BackgroundBDDCS Applied to Over 900 Drugs
Benet, L. Z., Broccatelli, F., & Oprea, T. I. (2011) · The AAPS Journal · doi:10.1208/s12248-011-9290-9 · Cited by 626
“Very recently, a consensus paper with respect to BCS, BDDCS, and regulatory guidances has been published (7).”
BackgroundSelf-citationBenet, L. Z. (2013) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23359 · Cited by 342
Self-citationPredicting Clearance Mechanism in Drug Discovery: Extended Clearance Classification System (ECCS)
Varma, M. V., Steyn, S. J., Allerton, C., & El-Kattan, A. F. (2015) · Pharmaceutical Research · doi:10.1007/s11095-015-1749-4 · Cited by 334
Nanotechnology as Emerging Tool for Enhancing Solubility of Poorly Water-Soluble Drugs
Kumar, S., Dilbaghi, N., Saharan, R., & Bhanjana, G. (2012) · BioNanoScience · doi:10.1007/s12668-012-0060-7 · Cited by 227
“BDDCS is applicable in condition where food and transporter interaction occur but BCS is not applicable for the same and also more number of drugs is available for biowaiver (drug product approval without a pharmacokinetic bioavailability and bioequivalence study) by BDDCS but less number of drugs is available for bio…”
BackgroundMethodInfluential
Metadata
- Authors
- Chen, M.-L., Amidon, G. L., Benet, L. Z., Lennernas, H., & Yu, L. X.
- Affiliations
- United States Food and Drug Administration (US)
- University of Michigan (US)
- University of California, San Francisco (US)
- Corresponding author
- Chen, Mei-Ling
- Venue
- Pharmaceutical Research
- Published
- 2011-04-14
- Volume
- 28
- Issue
- 7
- Pages
- 1774-1778
- ISSN
- 0724-8741 (ISSN-L)
- 1573-904X
- OpenAlex
- W2090138592
- Cited by
- 93
- References
- 19
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 5 · 2022: 5 · 2021: 2 · 2020: 2 · 2019: 7 · 2018: 5 · 2017: 7 · 2016: 7 · 2015: 13 · 2014: 7 · 2013: 16 · 2012: 11
- FWCI
- 10.57
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Pharmaceutical Research (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Healthcare Regulation
- Physical Sciences › Chemistry › Analytical Chemistry › Analytical Methods in Pharmaceuticals
- Keywords
- regulatory guidelines, biotechnology regulation
- MeSH terms
- Biopharmaceutics, Humans, Permeability, United States, United States Food and Drug Administration
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The BCS, BDDCS, and Regulatory Guidances. https://app.cochat.ai/papers/10.1007/s11095-011-0438-1
- The paper
- Chen, M.-L., Amidon, G. L., Benet, L. Z., Lennernas, H., & Yu, L. X. (2011). The BCS, BDDCS, and Regulatory Guidances. Pharmaceutical Research. https://doi.org/10.1007/s11095-011-0438-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.